| Literature DB >> 23786855 |
Guang-Rong Wang1, Li Li, Yi-Hui Pan, Guo-Dong Tian, Wan-Long Lin, Zhe Li, Zheng-Yi Chen, You-Long Gong, George E Kikano, Kurt C Stange, Ke-Liang Ni, Nathan A Berger.
Abstract
BACKGROUND: Metabolic risk factors and abnormalities such as obesity and hypertension are rapidly rising among the Chinese population following China's tremendous economic growth and widespread westernization of lifestyle in recent decades. Limited information is available about the current burden of metabolic syndrome (MetS) in China.Entities:
Mesh:
Year: 2013 PMID: 23786855 PMCID: PMC3734094 DOI: 10.1186/1471-2458-13-599
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Descriptive characteristics of “Health Zhabei 2020” survey adults (≥32 years)
| | | |||
|---|---|---|---|---|
| Age (years) | | 58.1(12.1) | 59.7(12.2) | <0.001 |
| Education level | ≤Middle school | 8177(60.3) | 4330(48.7) | <0.001 |
| | High school or profession school | 4357(32.1) | 2996(33.6) | |
| | ≥2-year college | 1022(7.5) | 1553(17.5) | |
| | missing | 9(0.1) | 13(0.2) | |
| Smoking | Yes | 334(2.5) | 4509(50.7) | <0.001 |
| | No | 13078(96.4) | 4265(48.0) | |
| | missing | 153(1.1) | 118(1.3) | |
| Alcohol Drinking | Yes | 392(2.9) | 3057(34.4) | <0.001 |
| | No | 13020(96.0) | 5717(64.3) | |
| | missing | 153(1.1) | 118(1.3) | |
| Family History | CHD | 1127(8.3) | 699(7.9) | 0.230 |
| | Diabetes mellitus | 845(6.2) | 501(5.6) | 0.065 |
| Personal History | CHD | 852(6.3) | 435(4.9) | <0.001 |
| | Diabetes mellitus | 1227(9.0) | 884(9.9) | 0.025 |
| SBP (mmHg) | | 125.4(15.8) | 128.5 (15.2) | <0.001 |
| DBP (mmHg) | | 79.1(8.9) | 81.4(9.3) | <0.001 |
| BMI (kg/m2) | | 24.1(4.4) | 24.2(3.9) | 0.047 |
| | <25 | 8766(64.6) | 5506(61.9) | <0.001 |
| | 25-30 | 4005(29.5) | 3042(34.2) | |
| | >30 | 790(5.8) | 342(3.9) | |
| Waist Circumference (cm) | | 81.0(9.7) | 86.4(9.2) | <0.001 |
| | Central obesitya | 4521(33.3) | 6989(78.6) | <0.001 |
| Waist-Hip Ratio | | 0.85(0.07) | 0.89(0.07) | <0.001 |
| Fasting Glucose (mg/dL) | | 97.3(27.0) | 99.1(30.6) | <0.001 |
| Triglycerides (mg/dL) | | 132.9(106.3) | 159.4(150.6) | <0.001 |
| HDL-C (mg/dL) | | 61.9(65.8) | 54.1(65.8) | <0.001 |
| LDL-C (mg/dL) | 116.0(34.8) | 112.1(30.9) | <0.001 |
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, HDL-C high density lipid cholesterol, LDL-C low density lipid cholesterol.
aWaist ≥ 85 cm for men, ≥ 80 cm for women according to joint interim criteria.
Prevalence of MetS components by gender according to the joint Interim consensus (IDF-C) and modified ATP III (ATPIII-M) criteria
| | ||||
|---|---|---|---|---|
| Abdominal obesity | 7328(54.0) | 5120(57.6) | 7328(54.0) | 3195(35.9) |
| Elevated blood pressure or hypertension | 7217(53.2) | 5571(62.7) | 7217(53.2) | 5571(62.7) |
| Hypertriglyceridemia | 4027(29.7) | 3197(36.0) | 4027(29.7) | 3197(36.0) |
| Low HDL-C | 3174(23.4) | 1146(12.9) | 683(5.0) | 1146(12.9) |
| High fasting Glucose or Diabetes | 3651(26.9) | 2763(31.1) | 2147(15.8) | 1671(18.8) |
IDF-C (joint interim consensus criteria by IDF and other organization): Diabetes or fasting glucose ≥ 100 mg/dL; Hypertension or SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; Dyslipidemia or HDL < 40 mg/dL for men and HDL < 50 mg/dL for women; Dyslipidemia or Triglycerides ≥ 150 mg/dL; Waist circumference ≥ 85 cm for men and ≥ 80 cm for women.
ATP III-M (modified NCEP ATP III criteria): Diabetes or fasting glucose ≥ 110 mg/dL; Hypertension or SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; Dyslipidemia or HDL < 40 mg/dL for both men and women; Dyslipidemia or Triglycerides ≥ 150 mg/dL; Waist circumference ≥ 90 cm for men and ≥ 80 cm for women.
Prevalence of MetS components according to the Interim consensus (IDF-C) or the modified NCEP ATP III (ATP III-M) criteria
| | ||||
|---|---|---|---|---|
| Met 5 criteria | 686(3.1) | 382(2.0) | 198(0.9) | 77(0.4) |
| Met 4 criteria | 2318(10.3) | 1667(8.6) | 1328(5.9) | 797(4.1) |
| Met 3 criteria | 4518(20.1) | 3497(18.1) | 3824(17.0) | 2761(14.3) |
| Met 2 criteria | 5776(25.7) | 5014(26.0) | 5953(26.5) | 5059(26.2) |
| Met 1 criteria | 5386(24.0) | 5026(26.1) | 6502(29.0) | 6031(31.3) |
| Met 0 criteria | 3773(16.8) | 3698(19.2) | 4652(20.7) | 4559(23.7) |
| total | 22457 | 19284 | 22457 | 19284 |
IDF-C (joint interim consensus criteria by IDF and other organization): Diabetes or fasting glucose ≥ 100 mg/dL; Hypertension or SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; Dyslipidemia or HDL < 40 mg/dL for men and HDL < 50 mg/dL for women; Dyslipidemia or Triglycerides ≥ 150 mg/dL; Waist circumference ≥ 85 cm for men and ≥ 80 cm for women.
ATP III-M (modified NCEP ATP III criteria): Diabetes or fasting glucose ≥ 110 mg/dL; Hypertension or SBP ≥ 130 mmHg or DBP ≥ 85mmHg; Dyslipidemia or HDL < 40 mg/dL for both men and women; Dyslipidemia or Triglycerides ≥ 150 mg/dL; Waist circumference ≥ 90cm for men and ≥ 80 cm for women.
Prevalence of MetS component by gender according to the Interim consensus (IDF-C) or the modified NCEP ATP III (ATP III-M) criteria
| | | | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 32-44 | 693(46.5) | 791(53.1) | 456(30.6) | 467(31.4) | 219(14.7) | 171(11.5) | 86(5.8) | 49(3.3) | 31(2.1) | 11(0.7) | 4(0.3) | 0(0.0) | 1489 |
| | 45-54 | 1145(24.5) | 1344(28.8) | 1368(29.3) | 1558(33.3) | 1076(23.0) | 1062(22.7) | 667(14.2) | 539(11.5) | 321(6.9) | 155(3.3) | 98(2.1) | 17(0.4) | 4675 |
| Female | 55-64 | 555(14.2) | 657(16.8) | 915(23.5) | 1082(27.7) | 1019(26.0) | 1150(29.5) | 814(20.9) | 722(18.5) | 448(11.5) | 257(6.6) | 153(3.9) | 36(0.9) | 3904 |
| | 65-74 | 109(6.0) | 121(6.6) | 298(16.4) | 387(21.2) | 507(27.8) | 605(33.2) | 493(27.1) | 511(28.1) | 300(16.5) | 174(9.6) | 114(6.2) | 23(1.3) | 1821 |
| | ≥75 | 66(3.9) | 87(5.2) | 271(16.2) | 341(20.4) | 472(28.2) | 594(35.4) | 490(29.2) | 466(27.8) | 277(16.5) | 166(9.9) | 100(6.0) | 22(1.3) | 1676 |
| | ||||||||||||||
| | 32-44 | 253(29.4) | 344(40.0) | 256(29.7) | 226(26.2) | 187(21.7) | 179(20.8) | 111(12.9) | 87(10.1) | 43(5.0) | 20(2.3) | 11(1.3) | 5(0.6) | 861 |
| | 45-54 | 409(16.9) | 536(22.2) | 545(22.5) | 709(29.3) | 636(26.3) | 603(24.9) | 518(21.4) | 394(16.3) | 253(10.5) | 153(6.3) | 58(2.4) | 24(1.0) | 2419 |
| Male | 55-64 | 328(11.2) | 475(16.2) | 678(23.1) | 880(30.0) | 827(28.2) | 794(27.1) | 684(23.4) | 546(18.7) | 337(11.5) | 204(7.0) | 76(2.6) | 31(1.1) | 2930 |
| | 65-74 | 123(8.4) | 173(11.8) | 304(20.6) | 450(30.5) | 455(30.9) | 435(29.5) | 378(25.6) | 298(20.2) | 176(11.9) | 97(6.6) | 38(2.6) | 21(1.4) | 1474 |
| | ≥75 | 92(7.6) | 124(10.3) | 295(24.4) | 402(33.3) | 378(31.3) | 360(29.8) | 277(23.0) | 212(17.5) | 132(10.9) | 91(7.5) | 34(2.8) | 19(1.6) | 1208 |
| | ||||||||||||||
| 32-44 | 946(40.3) | 1135(48.3) | 712(30.3) | 693(29.5) | 406(17.3) | 350(14.9) | 197(8.4) | 136(5.8) | 74(3.1) | 31(1.3) | 15(0.6) | 5(0.2) | 2350 | |
| | 45-54 | 1554(21.9) | 1880(26.5) | 1913(27.0) | 2267(32.0) | 1712(24.1) | 1665(23.5) | 1185(16.7) | 933(13.2) | 574(8.1) | 308(4.3) | 156(2.2) | 41(0.5) | 7094 |
| | 55-64 | 883(12.9) | 1132(16.6) | 1593(23.3) | 1962(28.7) | 1846(27.0) | 1944(28.4) | 1498(21.9) | 1268(18.6) | 785(11.5) | 461(6.7) | 229(3.4) | 67(1.0) | 6834 |
| | 65-74 | 232(7.0) | 294(8.9) | 602(18.3) | 837(25.4) | 962(29.2) | 1040(31.6) | 871(26.4) | 809(24.6) | 476(14.5) | 271(8.2) | 152(4.6) | 44(1.3) | 3295 |
| | ≥75 | 158(5.5) | 211(7.3) | 566(19.6) | 743(25.8) | 850(29.5) | 954(33.1) | 767(26.6) | 678(23.5) | 409(14.2) | 257(8.9) | 134(4.6) | 41(1.4) | 2884 |
IDF-C (joint interim consensus criteria by IDF and other organization): Diabetes or fasting glucose ≥ 100 mg/dL; Hypertension or SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; Dyslipidemia or HDL < 40 mg/dL for men and HDL < 50 mg/dL for women; Dyslipidemia or Triglycerides ≥ 150 mg/dL; Waist circumference ≥ 85 cm for men and ≥ 80 cm for women.
ATP III-M (modified NCEP ATP III criteria): Diabetes or fasting glucose ≥ 110 mg/dL; Hypertension or SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; Dyslipidemia or HDL < 40 mg/dL for both men and women; Dyslipidemia or Triglycerides ≥ 150 mg/dL; Waist circumference ≥ 90 cm for men and ≥ 80 cm for women.
Figure 1Prevalence of Metabolic Syndrome by Age and Gender, according to the Interim Consensus (IDF-C) and Modified NCEP ATP III (ATP III-M) Criteria.
Figure 2Prevalence of Metabolic Syndrome by Education and Gender, according to the Interim Consensus (IDF-C) and Modified NCEP ATP III (ATP III-M) Criteria.